ÌÇÐÄÆƽâ°æ

In 2025, the company had a total of 88,780 employees globally. This was a significantly lower figure when compared to, especially in 2018. In general, the number of employees at Bayer had remained stable until 2016, when Convestro, Bayer’s Material Science division, spun off into its own company. It increased again with the acquisition of Monsanto in 2018. 

Bayer’s company profile

Bayer works in about three segments globally: pharmaceuticals, consumer health, and crop science. In August 2019, Bayer agreed to sell its animal health division to Elanco. Bayer’s yearly revenues have been variable recently, but have still shown significant growth since the 1990s . Most recently, Bayer’s pharmaceutical and crop science segments have generated the most revenue for the company. Among Bayer’s pharmaceutical segment, the top pharmaceutical product is Xarelto, a blood-thinning agent. 

Bayer’s global positioning

As of 2024, Bayer was among the top pharmaceutical companies in many regards. Bayer ranks as 17th among the top 50 global pharmaceutical companies based on the sales of their prescription drugs. Bayer was also ranked as the ´Ú¾±´Ú³Ù³óÌý most valuable pharmaceutical brand in 2025. Other major pharmaceutical companies such as Roche, Pfizer, and AbbVie were listed among the most valuable pharmaceutical brands during that same year.